

Revised Draft Agenda

*Scientific Advisory Committee on
Alternative Toxicological Methods
October 20, 2004*

U.S. Environmental Protection
Agency, Building C, Room C111
(Auditorium sections A. and B), 109
T.W. Alexander Drive, Research
Triangle Park, NC 27709. (A photo ID is
required to access the EPA campus.)

8:30 a.m.

- Call to Order and Introductions
- Welcome and Remarks from the
National Institute of Environmental
Health Sciences (NIEHS) and the
National Toxicology Program (NTP)
- Welcome and Remarks from the
Interagency Coordinating Committee on
the Validation of Alternative Methods
(ICCVAM) Chair
- Update on Activities of the National
Toxicology Program (NTP) Interagency
Center for the Evaluation of Alternative
Toxicological Methods (NICEATM) and
ICCVAM
- Update on the European Center for
the Validation of Alternative Methods
(ECVAM) Workshop Recommendations
and Validation Studies
- Evaluation of the Under-Prediction
Rate for the *in vivo* Rabbit Dermal
Irritation Test
 - Public Comment
- Preliminary Evaluation of the
Under-Prediction Rate for the *in vivo*
Rabbit Ocular Irritation Test
 - Public Comment

12 p.m.: Lunch Break (on your own, the
EPA campus has a cafeteria)

1 p.m.

- ICCVAM Nominations
 - Public Comment
- NTP Roadmap
 - Public Comment
- ICCVAM Perspectives on Proposed
OECD Draft guidance Document on the
Validation and International Acceptance
of New or Updated Test methods for
Hazard Assessment (Guidance
Document 34)
- General Discussion

4:30 p.m.: Adjourn

Dated: October 8, 2004.

Samuel Wilson,

*Deputy Director, National Institute of
Environmental Health Sciences.*

[FR Doc. 04-23559 Filed 10-20-04; 8:45 am]

BILLING CODE 4140-01-P

**DEPARTMENT OF HEALTH AND
HUMAN SERVICES****National Institutes of Health****Prospective Grant of Exclusive
License: Human Parvovirus B19
Vaccine**

AGENCY: National Institutes of Health,
Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of a worldwide exclusive license to practice the inventions embodied in PCT/US89/04948 filed November 14, 1989, and National Stage filed in Australia (patent no. 631159), Canada (patent no. 1284268), Israel (patent no. 92298) and Japan (patent no. 2755817), entitled "Parvovirus Capsids"; U.S. patent no. 5,508,186, U.S. patent no. 6,132,732, U.S. patent no. 6,001,371, U.S. patent no. 5,827,647, entitled "B19 Parvovirus Capsids"; U.S. patent no. 5,916,563, U.S. patent no. 6,558,676 entitled "Parvovirus Capsids"; and PCT/NL90/00130 filed September 11, 1990, and National Stage filed in Europe (patent no. 0491824), Austria (patent no. 122395), Denmark (patent no. 0491824), Germany (patent no. 69019359), Netherlands (patent no. 8902301), Spain (patent no. 2073036) and United States (patent nos. 6,204,044, 6,287,815 and 6,379,885), entitled "Human Parvovirus B19 Proteins and Virus-like Particles, Their Production and Their Use in Diagnostic Assays and Vaccines" to Viral Antigens, Inc., having a place of business in Memphis, Tennessee. The patent rights in these inventions have been assigned or exclusively licensed to the United States of America.

DATES: Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before January 19, 2005, will be considered.

ADDRESSES: Requests for a copy of the patent application, inquiries, comments and other materials relating to the contemplated license should be directed to: Susan Ano, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804; e-mail: anos@od.nih.gov; telephone: (301) 435-5515; Facsimile: (301) 402-0220.

SUPPLEMENTARY INFORMATION: This technology describes a method of producing non-infectious recombinant human parvovirus B-19 capsids

composed of viral proteins VP1 and VP2 or VP2. The technology further relates to diagnostic assays utilizing the recombinantly produced parvovirus capsid proteins, or antibodies to such proteins. The technology also describes a vaccine effective against parvovirus B19 infection, consisting of the recombinant capsid proteins. Data from the inventors show that the configuration of the vaccine optimal for eliciting neutralizing antibodies comprises approximately twenty five percent (25%) VP1 and seventy five percent (75%) VP2. In another embodiment, the technology describes the use of parvovirus B19 viral capsids as a gene delivery system for proteins.

The prospective exclusive license will be royalty bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 90 days from the date of this published notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

The field of use may be limited to development of vaccines for parvovirus B19.

The licensed territory will be worldwide exclusive.

Properly filed competing applications for a license filed in response to this notice will be treated as objections to the contemplated license. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: October 14, 2004.

Steven M. Ferguson,

Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.

[FR Doc. 04-23561 Filed 10-20-04; 8:45 am]

BILLING CODE 4140-01-P

**DEPARTMENT OF HOMELAND
SECURITY****Directorate of Science and Technology**

[Docket No. DHS-2004-0008]

**Notice of Meeting of Homeland
Security Science and Technology
Advisory Committee**

AGENCY: Office of the Under Secretary for Science and Technology, DHS.

ACTION: Notice.

SUMMARY: The Homeland Security Science and Technology Advisory

Committee (HSSTAC) will meet in a partially closed session on November 15–16, 2004.

DATES: The HSSTAC will meet in closed session on November 15, 2004, from 8:30 a.m. to 4:30 p.m. and on November 16, 2004, from 8:30 a.m. to 10 a.m. The Committee will meet in open session on November 16, 2004, from 10 a.m. to 12 p.m.

ADDRESSES: The meeting location for the open session is Booz Allen Hamilton, Virginia Square Plaza, 3811 Fairfax Drive, Arlington, VA 22203.

FOR FURTHER INFORMATION CONTACT: Brenda Leckey, Homeland Security Science and Technology Advisory Committee, Department of Homeland Security, Directorate of Science and Technology, Washington, DC 20528; telephone (202) 254–5041; e-mail HSSTAC@dhs.gov.

SUPPLEMENTARY INFORMATION: Notice of this meeting is given under the Federal Advisory Committee Act (FACA), Pub. L. 92–463, as amended (5 U.S.C. app. 2). The HSSTAC will meet for purposes of receiving briefings from its subcommittees on recent activities and findings in support of the annual report to Congress, deliberating subcommittee findings and providing recommendations to the Under Secretary, and determining future subcommittee and committee activities. In accordance with section 10(d) of the Federal Advisory Committee Act, Pub. L. 92–463, as amended (5 U.S.C. app. 2), the Under Secretary for Science and Technology has determined that this HSSTAC meeting will concern unclassified but sensitive matters to homeland security within the meaning of 5 U.S.C. 552b(c)(9)(B) and that, accordingly, the meeting will be partially closed to the public.

Public Attendance: Due to meeting space restrictions, the maximum number of public attendees will be 20. Members of the public will be registered to attend the public session on a first-come, first-served basis per the procedures that follow. Any member of the public who wishes to attend the public session must provide his or her name, affiliation, social security number, and date of birth no later than 5 p.m. e.s.t., Monday, November 8, 2004. Please provide the required information to Brenda Leckey via e-mail at HSSTAC@dhs.gov, or via phone at (202) 254–5721. Persons with disabilities who require special assistance should indicate so in their admittance request. Photo identification will be required for entry into the public session, and everyone in attendance

must be present and seated by 10 a.m. on November 16, 2004.

Public Comments: You may submit comments, identified by DHS–2004–0008, by *one* of the following methods:

- EPA Federal Partner EDOCKET Web site: <http://www.epa.gov/feddoCKET>. Follow instructions for submitting comments on the Web site. The Department of Homeland Security has joined the Environmental Protection Agency (EPA) online public docket and comment system on its Partner Electronic Docket System (Partner EDOCKET). The Department of Homeland Security and its agencies (excluding the United States Coast Guard and Transportation Security Administration) will use the EPA Federal Partner EDOCKET system. The USCG and TSA [legacy Department of Transportation (DOT) agencies] will continue to use the DOT Docket Management System until full migration to the electronic rulemaking Federal docket management system in 2005.

- Federal eRulemaking Portal: <http://www.regulations.gov>. Follow the instructions for submitting comments.

- E-mail: hsstac@dhs.gov. Include DHS–2004–0008 in the subject line of the message.

- Fax: (202) 254–6177.

- Mail: Homeland Security Science and Technology Advisory Committee, Department of Homeland Security, Washington, DC 20528.

Instructions: All submissions received must include the agency name and docket number for this rulemaking. All comments received will be posted without change to <http://www.epa.gov/feddoCKET>, including any personal information provided.

Docket: For access to the docket to read background documents or comments received, go to <http://www.epa.gov/feddoCKET>.

Dated: October 14, 2004.

Charles E. McQueary,

Under Secretary for Science and Technology.

[FR Doc. 04–23575 Filed 10–20–04; 8:45 am]

BILLING CODE 4410–10–P

DEPARTMENT OF HOMELAND SECURITY

Coast Guard

[USCG–2004–19205]

Senior Executive Service Performance Review Board Membership

AGENCY: Coast Guard, DHS.

ACTION: Notice of appointments.

SUMMARY: The Coast Guard is providing notice of the appointment of 11

individuals to serve on its Performance Review Board.

FOR FURTHER INFORMATION CONTACT:

Ronald Kogut, Chief, Office of Civilian Personnel, (202) 267–0921.

SUPPLEMENTARY INFORMATION: Under 5 U.S.C. 4314(c)(4), the Coast Guard is required to publish the names of individuals appointed to serve on the Coast Guard Performance Review Board (CGPRB). The following 11 persons have been selected to serve on the CGPRB:

Rear Admiral K.T. Venuto, Assistant Commandant for Human Resources, United States Coast Guard;

Rear Admiral D.G. Gabel, Assistant Commandant for Acquisition, United States Coast Guard;

Rear Admiral L.L. Hereth, Director of Port Security, United States Coast Guard;

Rear Admiral R.D. Sirois, Assistant Commandant for Operations, United States Coast Guard;

Rear Admiral J.C. Van Sice, Director of Reserve and Training, United States Coast Guard;

Rear Admiral D.W. Kunkel, Director of Operations Capability, United States Coast Guard;

Rear Admiral J.W. Underwood, Director of Operations Policy, United States Coast Guard;

Rear Admiral E.M. Brown, Assistant Commandant for Systems, United States Coast Guard;

Mr. John Matticks, Senior Planning Advisor, Federal Emergency Management Agency;

Ms. Sheila Lumsden, Deputy Assistant Director for Human Resources and Training, U.S. Secret Service; and

Mr. Sam Russ, Executive Director for Tactical Communications, U.S. Customs and Border Protection.

Dated: October 15, 2004.

Ronald Kogut,

Chief, Office of Civilian Personnel.

[FR Doc. 04–23565 Filed 10–20–04; 8:45 am]

BILLING CODE 4910–15–P

DEPARTMENT OF THE INTERIOR

Bureau of Land Management

[AZ–030–1430 EU; AZA–32183]

Notice of Realty Action, Direct Sale of Public Lands in Mohave County, AZ

AGENCY: Bureau of Land Management, Interior.

ACTION: Notice of realty action, direct sale.

SUMMARY: The following public lands have been found suitable for a direct sale under the authority of section (203)